Allard Kaptein

3.7k total citations · 1 hit paper
39 papers, 2.3k citations indexed

About

Allard Kaptein is a scholar working on Molecular Biology, Genetics and Immunology. According to data from OpenAlex, Allard Kaptein has authored 39 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 13 papers in Genetics and 11 papers in Immunology. Recurrent topics in Allard Kaptein's work include Chronic Lymphocytic Leukemia Research (13 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Allard Kaptein is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Allard Kaptein collaborates with scholars based in Netherlands, United States and United Kingdom. Allard Kaptein's co-authors include Tjeerd Barf, Stuart Farrow, Karen Holloway, Margaret M. Manson, Simon Plummer, R. J. L. Munks, Lynne Howells, Michael A. Saunders, Todd Covey and Michael Gulrajani and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Blood.

In The Last Decade

Allard Kaptein

39 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex

1999 539 citations Simon Plummer, Karen Holloway et al. Oncogene profile →

Peers

Countries citing papers authored by Allard Kaptein

Since Specialization

Citations

This map shows the geographic impact of Allard Kaptein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allard Kaptein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allard Kaptein more than expected).

Fields of papers citing papers by Allard Kaptein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allard Kaptein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allard Kaptein. The network helps show where Allard Kaptein may publish in the future.

Co-authorship network of co-authors of Allard Kaptein

This figure shows the co-authorship network connecting the top 25 collaborators of Allard Kaptein. A scholar is included among the top collaborators of Allard Kaptein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allard Kaptein. Allard Kaptein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors 2022 ·Journal of Pharmacology and Experimental Therapeutics ·Terry Podoll, Paul G. Pearson, Allard Kaptein, Jerry Evarts, Gerjan de Bruin, (unknown), Anouk de Jong, Bart van Lith, Hao Sun, Stephen J. Byard, Adrian J. Fretland, (unknown), Tjeerd Barf, J. Greg Slatter	15
2	Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors 2021 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Dennis Demont, Edwin de Zwart, (unknown), (unknown), Bas van de Kar, Allard Kaptein, Tjeerd Barf	2
3	Phosphoflow Protocol for Signaling Studies in Human and Murine B Cell Subpopulations 2020 ·The Journal of Immunology ·Jasper Rip, Marjolein J. W. de Bruijn, Allard Kaptein, Rudi W. Hendriks, Odilia B. J. Corneth	24
4	Discovery of quinoline-based irreversible BTK inhibitors 2020 ·Bioorganic & Medicinal Chemistry Letters ·Gerjan de Bruin, Dennis Demont, Edwin de Zwart, (unknown), (unknown), Bas van de Kar, Bart van Lith, (unknown), Michael Gulrajani, Todd Covey, Allard Kaptein, Tjeerd Barf	7
5	Chemical genetics strategy to profile kinase target engagement reveals role of FES in neutrophil phagocytosis 2020 ·Nature Communications ·Tom van der Wel, Riet Hilhorst, Hans den Dulk, (unknown), (unknown), (unknown), Bogdan I. Florea, Eelke B. Lenselink, Gerard J. P. van Westen, Rob Ruijtenbeek, Herman S. Overkleeft, Allard Kaptein, Tjeerd Barf, Mario van der Stelt	9
6	Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies 2018 ·Blood ·Allard Kaptein, Gerjan de Bruin, (unknown), Bas van de Kar, Anouk de Jong, Michael Gulrajani, Dennis Demont, Todd Covey, Diana Mittag, Tjeerd Barf	71
7	Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile 2017 ·Journal of Pharmacology and Experimental Therapeutics ·Tjeerd Barf, Todd Covey, Raquel Izumi, Bas van de Kar, Michael Gulrajani, Bart van Lith, (unknown), Edwin de Zwart, Diana Mittag, Dennis Demont, (unknown), Fanny Krantz, Paul G. Pearson, Roger G. Ulrich, Allard Kaptein	272
8	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Sarah E. M. Herman, Arnau Montraveta, Carsten Utoft Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger G. Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner, Jennifer A. Woyach	121
9	Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma 2016 ·PLoS ONE ·Bonnie K. Harrington, Heather L. Gardner, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kevin R. Coombes, Todd Covey, Allard Kaptein, Michael Gulrajani, Bart van Lith, Cecile M. Krejsa, Christopher C. Coss, Duncan S. Russell, Xiaoli Zhang, (unknown), Cheryl A. London, John C. Byrd, Amy J. Johnson, William C. Kisseberth	43
10	Structure-based lead identification of ATP-competitive MK2 inhibitors 2011 ·Bioorganic & Medicinal Chemistry Letters ·Tjeerd Barf, Allard Kaptein, (unknown), (unknown), (unknown), Dennis Demont, Carsten Schultz‐Fademrecht, (unknown), (unknown), (unknown), Bert Kazemier, Bas van de Kar, (unknown), (unknown), (unknown), Ruben L. Smeets, Claudia L. Hofstra, Jorrit J. Hornberg, Arthur Oubrie	19
11	Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series 2011 ·Bioorganic & Medicinal Chemistry Letters ·Arthur Oubrie, Allard Kaptein, Edwin de Zwart, (unknown), (unknown), Bas van de Kar, (unknown), (unknown), (unknown), (unknown), Bert Kazemier, (unknown), (unknown), Jos P. M. Lommerse, Carsten Schultz‐Fademrecht, Tjeerd Barf	13
12	Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors 2011 ·Bioorganic & Medicinal Chemistry Letters ·Allard Kaptein, Arthur Oubrie, Edwin de Zwart, (unknown), (unknown), Bas van de Kar, (unknown), (unknown), (unknown), Carsten Schultz‐Fademrecht, (unknown), (unknown), (unknown), Bert Kazemier, (unknown), (unknown), John Dulos, Martin Jaeger, (unknown), Tjeerd Barf	17
13	Tumour necrosis factor-α stimulates dehydroepiandrosterone metabolism in human fibroblast-like synoviocytes: a role for nuclear factor-κB and activator protein-1 in the regulation of expression of cytochrome p450 enzyme 7b 2005 ·Arthritis Research & Therapy ·John Dulos, Allard Kaptein, Annemieke Kavelaars, Cobi J. Heijnen, Annemieke M. H. Boots	17
14	Severity of murine collagen‐induced arthritis correlates with increased CYP7B activity: Enhancement of dehydroepiandrosterone metabolism by interleukin‐1β 2004 ·Arthritis & Rheumatism ·John Dulos, (unknown), Wilma M. Bagchus, Annemieke M. H. Boots, Allard Kaptein	35
15	Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex breakdown → 1999 ·Oncogene ·Simon Plummer, Karen Holloway, Margaret M. Manson, R. J. L. Munks, Allard Kaptein, Stuart Farrow, Lynne Howells	539
16	No Effect of Fibrates on Synthesis of Apolipoprotein(a) in Primary Cultures of Cynomolgus Monkey and Human Hepatocytes: Apolipoprotein A-I Synthesis Increased 1998 ·Biochemical and Biophysical Research Communications ·(unknown), Allard Kaptein, Holger Huisman, (unknown), P. Hans	9
17	Dominant Negative Stat3 Mutant Inhibits Interleukin-6-induced Jak-STAT Signal Transduction 1996 ·Journal of Biological Chemistry ·Allard Kaptein, (unknown), Michael A. Saunders	215
18	Butyrate stimulates the secretion of apolipoprotein B-100-containing lipoproteins from HepG2 cells by inhibiting the intracellular degradation 1994 ·Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·Allard Kaptein, E.C.M. de Wit, P. Hans	7
19	Butyrate stimulates the secretion of apolipoprotein A-I and apolipoprotein B-100 in Hep G2 cells by different mechanisms 1992 ·Clinical Biochemistry ·Allard Kaptein, (unknown), P. Hans	4
20	Molecular cloning of chromosome I DNA from Saccharomyces cerevisiae: localization of a repeated sequence containing an acid phosphatase gene near a telomere of chromosome I and chromosome VIII 1989 ·Current Genetics ·H. Yde Steensma, Peter de Jonge, Allard Kaptein, David B. Kaback	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact